MZT2A and neoplasm: Collectively, these findings suggest that MZT2A is involved in immune cell infiltration and the tumor microenvironment, may contribute to KIRC progression, and is overexpressed in cases with poor prognosis, supporting its potential as a diagnostic and prognostic biomarker.